MediPharm Labs Corp (CVE:LABS) (OTCMKTS:MLCPF) CEO Keith Strachan shares details of the company’s blockbuster deal with a private buyer. Strachan explains that the agreement is for 75-80 percent pure crude resin medical concentrates with the option for further sales worth $13 million. The 13 month contract creates stability for MediPharm. The deal builds on MediPharm’s existing supply agreements with big names like Canopy Growth Corp (TSE:WEED) (NYSE:CGC) (FRA:11L1). The company generated $10 million in sales in December and Strachan believes it is well-positioned for acquisition and expansion opportunities. MediPharm has expanded internationally and its facility near Melbourne, Australia is waiting for government licenses.
************************
Check out our website:
https://midasletter.com
************************
SUBSCRIBE to our YouTube:
http://bit.ly/MidasLetterYoutube
SUBSCRIBE to our 2nd YouTube Channel – Midas Letter Clips:
https://bit.ly/2rtQzgy
SUBSCRIBE to our Newsletter:
http://bit.ly/MidasLetterNewsletter
Download Our Podcast on iTunes:
http://bit.ly/MidasLetterPodcast
************************
Follow Us on Twitter:
http://bit.ly/MidasLetterTwitter
Like Us on Instagram:
http://bit.ly/MidasLetterInsta
Like Us on Facebook:
http://bit.ly/MidasLetterFacebook
************************
#WeedStocks
#MidasLetter
source